產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-PKD1L3抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-PKD1L3抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-PKD1L3
Cat. Number:
Anti-PKD1L3抗體KL-11622R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Polycystin-1L3 is a 1,732 amino acid multi-pass membrane protein that contains one PLAT domain, one GPS domain and one C-type lectin domain. Expressed at high levels in placenta and present at lower levels in lung and heart, Anti-PKD1L3抗體Polycystin-1L3 is thought to function as an ion-channel regulator that may interact with Polycystin-L and play a role in heteromeric taste channels. The gene encoding Polycystin-1L3 maps to human chromosome 16, which encodes over 900 genes and comprises nearly 3% of the human genome. The GAN gene is located on chromosome 16 and, with mutation, may lead to giant axonal neuropathy, a nervous system disorder characterized by increasing malfunction with growth. The rare disorder Rubinstein-Taybi syndrome is also associated with chromosome 16, as is Crohn's disease, which is a gastrointestinal inflammatory condition.
Also known as:
PC1 like 3 protein; Polycystic kidney disease 1 like 3; Polycystic kidney disease protein 1 like 3; Polycystin 1 like 3; Polycystin Anti-PKD1L3抗體1L3;PK1L3_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, .
●
Immunogen: KLH conjugated synthetic peptide derived from human PKD1L3.
●
Predicted Molecular Weight: Anti-PKD1L3抗體193kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-PKD1L3抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
